Remarkably, patients with CLN2 disease in this study were diagnosed at a mean age of 38.7 months with a mean time from seizure onset to diagnosis of 10 months, a significantly shorter time compared to natural history diagnostic data [34], demonstrating that use of a comprehensive epilepsy gene panel can effectively and timely diagnose patients with CLN2 disease. This evidence concerns the gene TPP1 and epilepsy.